Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$5.16
-4.3%		$4.24
$2.93
▼
$7.55
$676.51M1.493.79 million shs3.66 million shs
Evolus, Inc. stock logo
EOLS
Evolus
$8.88
+1.1%		$7.00
$3.86
▼
$9.12
$579.92M1.351.14 million shs1.19 million shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$6.03
$6.92
$4.91
▼
$13.46
$599.67M0.981.93 million shs1.19 million shs
TerrAscend Corp. stock logo
TRSSF
TerrAscend
$0.60
-3.2%		$0.58
$1.62
▼
$1.80
$149.88M2.89131,026 shs600,291 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
+6.10%+17.43%+44.50%+34.08%+38.21%
Evolus, Inc. stock logo
EOLS
Evolus
-2.23%+2.09%+42.07%+33.64%+14.77%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
+5.42%-5.49%+4.69%-35.85%-56.59%
TerrAscend Corp. stock logo
TRSSF
TerrAscend
+2.43%+9.45%+13.43%-9.53%-43.06%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$5.16
-4.3%		$4.24
$2.93
▼
$7.55
$676.51M1.493.79 million shs3.66 million shs
Evolus, Inc. stock logo
EOLS
Evolus
$8.88
+1.1%		$7.00
$3.86
▼
$9.12
$579.92M1.351.14 million shs1.19 million shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$6.03
$6.92
$4.91
▼
$13.46
$599.67M0.981.93 million shs1.19 million shs
TerrAscend Corp. stock logo
TRSSF
TerrAscend
$0.60
-3.2%		$0.58
$1.62
▼
$1.80
$149.88M2.89131,026 shs600,291 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
+6.10%+17.43%+44.50%+34.08%+38.21%
Evolus, Inc. stock logo
EOLS
Evolus
-2.23%+2.09%+42.07%+33.64%+14.77%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
+5.42%-5.49%+4.69%-35.85%-56.59%
TerrAscend Corp. stock logo
TRSSF
TerrAscend
+2.43%+9.45%+13.43%-9.53%-43.06%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
3.00
Buy$8.8070.54% Upside
Evolus, Inc. stock logo
EOLS
Evolus
2.50
Moderate Buy$14.5063.29% Upside
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
2.50
Moderate Buy$28.20367.66% Upside
TerrAscend Corp. stock logo
TRSSF
TerrAscend
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TRSSF, AQST, EOLS, and SPRY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/25/2026
Evolus, Inc. stock logo
EOLS
Evolus
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$13.00
8/24/2026
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$10.00
8/17/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/25/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$25.00 ➝ $24.00
6/17/2026
Evolus, Inc. stock logo
EOLS
Evolus
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$13.00
6/15/2026
Evolus, Inc. stock logo
EOLS
Evolus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/1/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
5/29/2026
Evolus, Inc. stock logo
EOLS
Evolus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
5/28/2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$12.00 ➝ $30.00
(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$54.09M11.97N/AN/A($0.45) per share-11.47
Evolus, Inc. stock logo
EOLS
Evolus
$297.18M1.97N/AN/A($0.47) per share-18.89
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$84.28M7.12N/AN/A$0.13 per share46.38
TerrAscend Corp. stock logo
TRSSF
TerrAscend
$247.83M0.60N/AN/A$1.28 per share0.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$83.78M-$0.65N/AN/AN/A-144.63%N/A-52.40%11/4/2026 (Estimated)
Evolus, Inc. stock logo
EOLS
Evolus
-$51.64M-$0.52N/A111.00N/A-10.85%N/A-13.00%11/4/2026 (Estimated)
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$171.30M-$2.18N/AN/AN/A-184.24%-256.67%-69.63%11/9/2026 (Estimated)
TerrAscend Corp. stock logo
TRSSF
TerrAscend
-$329.91M-$0.14N/AN/AN/A-125.03%-6.66%-3.07%N/A

Latest TRSSF, AQST, EOLS, and SPRY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.4777-$0.63-$0.1523-$0.63$31.32 million$33.66 million
8/11/2026Q2 2026
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.1050-$0.18-$0.0750-$0.18$11.42 million$13.82 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
N/AN/AN/AN/AN/A
TerrAscend Corp. stock logo
TRSSF
TerrAscend
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/A
7.19
6.74
Evolus, Inc. stock logo
EOLS
Evolus
N/A
1.70
1.28
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
13.72
3.48
3.28
TerrAscend Corp. stock logo
TRSSF
TerrAscend
0.55
0.73
0.40

Institutional Ownership

CompanyInstitutional Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
32.45%
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
68.16%
TerrAscend Corp. stock logo
TRSSF
TerrAscend
0.04%

Insider Ownership

CompanyInsider Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
6.81%
Evolus, Inc. stock logo
EOLS
Evolus
5.00%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
33.80%
TerrAscend Corp. stock logo
TRSSF
TerrAscend
32.93%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
160125.51 million116.97 millionOptionable
Evolus, Inc. stock logo
EOLS
Evolus
17066.05 million62.75 millionOptionable
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
9099.45 million65.83 millionOptionable
TerrAscend Corp. stock logo
TRSSF
TerrAscend
740251.86 million168.93 millionNot Optionable

Recent News About These Companies

TerrAscend Renews $10 Million Share Buyback to Boost Investor Value
August 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/terrascend-renews-10-million-share-buyback-to-boost-investor-value?utm_source=marketbeat.com&utm_medium=referral
TerrAscend Strengthens Balance Sheet With New Convertible Debentures
June 25, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/terrascend-strengthens-balance-sheet-with-new-convertible-debentures?utm_source=marketbeat.com&utm_medium=referral
TerrAscend Shareholders Back Board Slate and Incentive Plans
June 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/terrascend-shareholders-back-board-slate-and-incentive-plans?utm_source=marketbeat.com&utm_medium=referral
TerrAscend Appoints Eric Jackson as New CFO
April 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/terrascend-appoints-eric-jackson-as-new-cfo?utm_source=marketbeat.com&utm_medium=referral
TerrAscend Sets March Date to Report 2025 Results and Hold Earnings Call
February 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/terrascend-sets-march-date-to-report-2025-results-and-hold-earnings-call?utm_source=marketbeat.com&utm_medium=referral
TerrAscend expands New Jersey footprint with Union Chill deal
December 30, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/terrascend-expands-new-jersey-footprint-with-union-chill-deal?utm_source=marketbeat.com&utm_medium=referral
TerrAscend Renews $10 Million Share Repurchase Program
August 20, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/terrascend-renews-10-million-share-repurchase-program?utm_source=marketbeat.com&utm_medium=referral
TerrAscend Corp. (TSNDF) Q2 2025 Earnings Call Transcript
August 8, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4811512-terrascend-corp-tsndf-q2-2025-earnings-call-transcript
TerrAscend Reports Second Quarter 2025 Financial Results
August 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/07/3129719/0/en/TerrAscend-Reports-Second-Quarter-2025-Financial-Results.html
TerrAscend Corp Expands Loan for Growth Initiatives
July 9, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/terrascend-corp-expands-loan-for-growth-initiatives?utm_source=marketbeat.com&utm_medium=referral
TerrAscend Corp. (TSNDF) Q1 2025 Earnings Call Transcript
May 8, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4784088-terrascend-corp-tsndf-q1-2025-earnings-call-transcript
TerrAscend Reports First Quarter 2025 Financial Results
May 8, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/08/3077769/0/en/TerrAscend-Reports-First-Quarter-2025-Financial-Results.html
TerrAscend Corp. (TSNDF) Q4 2024 Earnings Call Transcript
March 6, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4765540-terrascend-corp-tsndf-q4-2024-earnings-call-transcript
TerrAscend Reports Steady Q4 Growth Amid Market Challenges
January 31, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/terrascend-reports-steady-q4-growth-amid-market-challenges?utm_source=marketbeat.com&utm_medium=referral
TerrAscend Corp Promotes Lynn Gefen to Key Role
November 26, 2024  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/terrascend-corp-promotes-lynn-gefen-to-key-role?utm_source=marketbeat.com&utm_medium=referral
Cannabis Stocks Plunged After Florida Legalization Failed: Rational Reaction Or Market Overreach?
November 9, 2024  |  benzinga.comhttps://www.benzinga.com/markets/cannabis/24/11/41855573/cannabis-stocks-plunged-after-florida-legalization-failed-rational-reaction-or-market-overreach
TerrAscend Expands Footprint Despite Q3 Losses, Can A Move To Ohio Turn The Tide?
November 6, 2024  |  benzinga.comhttps://www.benzinga.com/markets/cannabis/24/11/41791053/terrascend-expands-footprint-despite-q3-losses-can-a-move-to-ohio-turn-the-tide
TerrAscend Corp Stock (OTC:TRSSF), Short Interest Report
October 21, 2023  |  benzinga.comhttps://www.benzinga.com/quote/TRSSF/short-interest
Which Is the Better Cannabis Growth Stock for You: Cresco Labs or TerrAscend?
October 19, 2023  |  msn.comhttps://www.msn.com/en-us/money/markets/which-is-the-better-cannabis-growth-stock-for-you-cresco-labs-or-terrascend/ar-AA1ivdPX
EXCLUSIVE: Why TerrAscend's Success Doesn't Rely On Federal Cannabis Reform
September 28, 2023  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/exclusive-why-terrascend-s-success-doesn-t-rely-on-federal-cannabis-reform-1032664490

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aquestive Therapeutics stock logo

Aquestive Therapeutics NASDAQ:AQST

$5.16 -0.23 (-4.27%)
Closing price 04:00 PM Eastern
Extended Trading
$5.19 +0.03 (+0.58%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Evolus stock logo

Evolus NASDAQ:EOLS

$8.88 +0.10 (+1.14%)
Closing price 04:00 PM Eastern
Extended Trading
$8.86 -0.02 (-0.27%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

ARS Pharmaceuticals stock logo

ARS Pharmaceuticals NASDAQ:SPRY

$6.03 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$6.03 +0.00 (+0.02%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

TerrAscend stock logo

TerrAscend OTCMKTS:TRSSF

$0.60 -0.02 (-3.24%)
As of 08/26/2026

TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures cannabis-infused artisan edibles. It also operates retail dispensaries under the Apothecarium brand name in California, Pennsylvania, and New Jersey. In addition, the company owns various synergistic businesses under Gage Growth, Pinnacle, TerrAscend NJ, Ilera Healthcare, HMS Health and HMS Processing, Valhalla Confections, State Flower, Arise Bioscience Inc., and TerrAscend Canada brands. It serves medical and legal adult-use markets. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas